Premature ovarian insufficiency, previously known as premature ovarian failure, is a condition characterised by the loss of ...

Researchers at Bar-Ilan University have discovered that changing just one letter in DNA can completely alter sex development ...

The FDA has granted Fast Track designation to the investigational antibody-drug conjugate (ADC) SIM0505 for the treatment of women with platinum-resistant ovarian cancer. The designation adds SIM0505 ...

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable ...

Bar-Ilan University researchers use CRISPR tool to alter Enh13 switch controlling Sox9 gene, causing XX mice to develop as males; study may help explain other genetic mutations The post With a switch ...

Gilead Sciences' latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline. Gilead on Tuesday ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ...

OverT Bio, a biotechnology company developing next-generation therapies for solid tumors, today announced the formation of its Clinical Advisory Board, comprised of internationally recognized leaders ...